<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lederman, Lynne</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Klein, Eric J.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Once Weekly Exenatide is Safe and Effective for Long-term T2DM Treatment</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014-11-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">23-24</style></pages><abstract><style  face="normal" font="default" size="100%">Patients with type 2 diabetes mellitus (T2DM) require long-term treatment with a hypoglycemic agent, but these agents can be difficult in terms of patient adherence. This article presents 6-year follow-up data on the efficacy of a once-weekly formulation of exenatide. The phase 3 Effects of Exenatide Long-Acting Release on Glucose Control and Safety in Subjects With Type 2 Diabetes Mellitus [DURATION-1; NCT00308139] is the longest assessment of a glucagon-like peptide–1 receptor agonist reported to date.</style></abstract><number><style face="normal" font="default" size="100%">32</style></number><volume><style face="normal" font="default" size="100%">14</style></volume></record></records></xml>